Jiang Zhong Pharmaceutical Co Ltd banner

Jiang Zhong Pharmaceutical Co Ltd
SSE:600750

Watchlist Manager
Jiang Zhong Pharmaceutical Co Ltd Logo
Jiang Zhong Pharmaceutical Co Ltd
SSE:600750
Watchlist
Price: 23.99 CNY -3.73%
Market Cap: ¥15.2B

EV/OCF

16.2
Current
26%
More Expensive
vs 3-y average of 12.8

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
16.2
=
Enterprise Value
¥13.9B
/
Operating Cash Flow
¥826m

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
16.2
=
Enterprise Value
¥13.9B
/
Operating Cash Flow
¥826m

Valuation Scenarios

Jiang Zhong Pharmaceutical Co Ltd is trading above its 3-year average

If EV/OCF returns to its 3-Year Average (12.8), the stock would be worth ¥19.05 (21% downside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-36%
Maximum Upside
+47%
Average Upside
5%
Scenario EV/OCF Value Implied Price Upside/Downside
Current Multiple 16.2 ¥23.99
0%
3-Year Average 12.8 ¥19.05
-21%
5-Year Average 10.3 ¥15.28
-36%
Industry Average 23.8 ¥35.27
+47%
Country Average 20.8 ¥30.87
+29%

Forward EV/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward EV/OCF

Peer Comparison

All Multiples
EV/OCF
P/E
All Countries
Close
Market Cap EV/OCF P/E
CN
Jiang Zhong Pharmaceutical Co Ltd
SSE:600750
15.2B CNY 16.2 16.7
US
Eli Lilly and Co
NYSE:LLY
825.8B USD 51.1 40
US
Johnson & Johnson
NYSE:JNJ
548.5B USD 23.4 26.1
CH
Roche Holding AG
SIX:ROG
248.4B CHF 15.2 20.1
UK
AstraZeneca PLC
LSE:AZN
215.6B GBP 21 27.9
CH
Novartis AG
SIX:NOVN
218.9B CHF 15.3 19.6
US
Merck & Co Inc
NYSE:MRK
272.3B USD 18.5 14.9
IE
Endo International PLC
LSE:0Y5F
244.4B USD 936 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 10.7 11.5
US
Pfizer Inc
NYSE:PFE
150.6B USD 17 19.4
US
Bristol-Myers Squibb Co
NYSE:BMY
117.3B USD 10.6 16.6
P/E Multiple
Earnings Growth PEG
CN
Jiang Zhong Pharmaceutical Co Ltd
SSE:600750
Average P/E: 21.3
16.7
11%
1.5
US
Eli Lilly and Co
NYSE:LLY
40
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.1
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.9
25%
1.1
CH
Novartis AG
SIX:NOVN
19.6
14%
1.4
US
Merck & Co Inc
NYSE:MRK
14.9
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.4
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.6
16%
1

Market Distribution

In line with most companies in China
Percentile
41th
Based on 6 190 companies
41th percentile
16.2
Low
0 — 11.5
Typical Range
11.5 — 39.2
High
39.2 —
Distribution Statistics
China
Min 0
30th Percentile 11.5
Median 20.8
70th Percentile 39.2
Max 266 666.7

Jiang Zhong Pharmaceutical Co Ltd
Glance View

Market Cap
15.2B CNY
Industry
Pharmaceuticals

Jiang Zhong Pharmaceutical Co Ltd. has etched its mark in the bustling landscape of China's pharmaceutical industry by embracing a strategic blend of traditional Chinese medicine (TCM) and modern medical practices. Founded in 1969 and headquartered in Wuhan, this company has steadily navigated the dynamic tides of China's healthcare sector. Jiang Zhong specializes in producing and marketing a wide array of TCM products, which are deeply rooted in ancient Chinese medical philosophies and practices. These offerings cater to various health needs, including gastrointestinal management, respiratory treatments, and nutritional supplements, which resonate well with China's rich cultural heritage of natural health solutions. The company's commitment to quality and efficacy has allowed it to carve out a substantial market niche where tradition meets innovation. Making money for Jiang Zhong Pharmaceutical Co Ltd. revolves around its robust distribution networks and strong brand presence across key domestic markets. The company has invested in extensive research and development initiatives to ensure its product line remains relevant and effective in addressing modern health challenges, alongside its traditional product offerings. By leveraging a diverse marketing strategy that includes partnerships with healthcare institutions, direct consumer promotions, and digital platforms, Jiang Zhong successfully taps into both local and international markets. Additionally, the company enhances its profitability through economies of scale and strategic cost management, allowing it to maintain competitive pricing while achieving substantial revenue growth. This balanced approach of blending tradition with innovation continues to fortify Jiang Zhong Pharmaceutical's position as a respected entity in both TCM and broader pharmaceutical realms.

Intrinsic Value
27.76 CNY
Undervaluation 14%
Intrinsic Value
Price ¥23.99
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett